Instil Bio
98 hedge funds and large institutions have $551M invested in Instil Bio in 2022 Q2 according to their latest regulatory filings, with 29 funds opening new positions, 32 increasing their positions, 19 reducing their positions, and 7 closing their positions.
314% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 7
68% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 19
26% more funds holding
Funds holding: 78 → 98 (+20)
0.89% more ownership
Funds ownership: 91.34% → 92.23% (+0.89%)
4% less capital inflows, than outflows
Capital inflows: $65.9M | Capital outflows: $68.7M
20% less funds holding in top 10
Funds holding in top 10: 5 → 4 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RA Capital Management
Boston,
Massachusetts
|
+$19.8M |
| 2 |
ArrowMark Colorado Holdings
Denver,
Colorado
|
+$8.93M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$8.87M |
| 4 |
BlackRock
New York
|
+$5.94M |
| 5 |
Renaissance Technologies
New York
|
+$2.51M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HHLR Advisors
Grand Cayman,
Cayman Islands
|
-$25.6M |
| 2 |
AllianceBernstein
Nashville,
Tennessee
|
-$21M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$9.28M |
| 4 |
VR Adviser
New York
|
-$6.14M |
| 5 |
Nicholas Investment Partners
Rancho Santa Fe,
California
|
-$2.26M |
TIL Hedge Fund Activity: Q2 2022 in Review
98 of the 5,963 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q2 2022, worth a combined $551M — down 57% from $1.27B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new TIL positions and 7 closed out — a net gain of 22 holders — while 32 added to existing stakes and 19 trimmed.
The largest buyer was RA Capital Management, adding an estimated $19.8M. The largest seller was HHLR Advisors, exiting entirely with an estimated $25.6M sold.
- 98 institutional investors held Instil Bio (TIL) as of Q2 2022, up from 78 in Q1 2022.
- Funds reported $551M of Instil Bio stock for Q2 2022, down 57% quarter-over-quarter.
- 29 funds opened new Instil Bio positions in Q2 2022 and 7 closed out, a net change of +22 holders.
- The largest Instil Bio buyer in Q2 2022 was RA Capital Management, an estimated $19.8M added.
- The largest Instil Bio seller in Q2 2022 was HHLR Advisors, an estimated $25.6M sold.
Based on aggregated 13F filings for Q2 2022.